Protein ubiquitination is a key regulator of both protein stability and activity, and is involved in the regulation of a vast variety of cellular pathways. The ubiquitination system therefore provides an exciting target for drug development aiming to regulate the function of specific proteins. Our understanding of ubiquitin signalling is far from complete; and if we are to exploit this system for the benefit of human health, it is important to gain a better understanding of this complex posttranslational modification system as well as the effect of ubiquitination on the target protein. The E3 ligases MDM2 and CHIP were implicated in the control of the two transcriptional activators (TAs) IRF-1 and p53, that normally function to maintain health at the cellular and organismal level. Research carried out as part of my PhD has focused on gaining a mechanistic understanding of the ubiquitination process in particular the relationship between the E3 ligase and its substrate. Broadly, the mechanisms of E3 ligase regulation have been linked to substrate specificity and then to the physiological outcome of site-specific ubiquitination of the DNA binding domain of the TAs IRF-1 and p53. More specifically I have; (i) identified a mechanism by which the E3 ligase activity of the CHIP U-box can be allosterically regulated by ligand binding to its TPR domain. (ii) Residues on IRF-1 that are targeted by MDM2 and CHIP have been mapped, revealing that both ligases modify sites exclusively in IRF-1's DNA binding domain (DBD). Furthermore, I showed that, in its DNA bound conformation, IRF-1 is neither bound nor ubiquitinated by the ligases, suggesting a mechanism by which IRF-1 ubiquitination and possibly degradation can be regulated through its DNA binding state. And lastly, (iii) I have shown that both IRF-1 and p53, which have ubiquitin acceptor lysines in their DBD, bind DNA more stably when ubiquitinated. Modelling suggests that interactions between a positively charged surface area of ubiquitin and the negatively charged DNA can stabilises the TA-ubiquitin complex. DBD ubiquitination sites are required for full transactivation potential of both TAs, supporting a role of ubiquitin in their activation. p53 is ubiquitinated in response to activation by IR or Nutlin-3 and these ubiquitinated forms of p53 are localised in the cell nucleus associated with chromatin and do not lead to protein degradation. Taken together, the data imply that p53 and IRF-1 DNA binding ability, and thereby activity, can be modulated by ubiquitin modification.

As E3 ligases MuRF1 e MuRF2 tem sido descritas com importantes papéis na estabilidade de proteínas da estrutura muscular, além de contribuírem para marcação de proteínas que devem ser degradadas. Nosso objetivo foi verificar o papel de MuRF1 e MuRF2 na diferenciação de células miogênicas, além de caracterizar seu papel em fibroblastos. Foram utilizados animais nocautes para MuRF1 e MuRF2 e verificamos o processo de regeneração 28 dias após a injeção de cardiotoxina no tibial anterior. Posteriormente, através de análises in vitro, realizamos o silenciamento de MuRF1 e MuRF2 utilizando RNAis e verificamos a capacidade de diferenciação de células miogênicas. Os resultados mostram que os animais nocautes apresentaram aumento de marcadores adipogênicos. Além disso, as células silenciadas com RNAis apresentaram queda na formação de miotubos e um aumento em marcadores adipogênicos. Em fibroblastos, identificamos as E3 ligases MuRF1 e MuRF2 e o RNAi nessas células prejudicou o processo de migração. Esses resultados realçam a importância de MuRF1 e MuRF2 na diferenciação miogênica além de sugerir um importante papel para a formação correta do citoesqueleto durante a migração celular. / The E3 ligases MuRF1 and MuRF2 has been proposed to act as a linker for myofibril machinery, also by acting as an Atrogene during muscle wasting. Our aim was to verify the role of MuRF1 and MuRF2 during the myogenic differentiation of skeletal muscle and its role on skeletal muscle fibroblasts. We used MuRF1 and MuRF2 knockout mice and analyzed the regenerative process. Using in vitro analyzes, we silenced MuRF1 and MuRF2 expression by siRNA. Our results suggest that knockout mice had an important impairment on skeletal muscle regeneration, showing positive staining to white adipocytes. Moreover, siRNA on myogenic primary cultures showed impaired myotube formation and increase the expression of adipogenic markers. Another interesting finding was that skeletal muscle fibroblasts can express MuRF1 and MuRF2, and its silencing by siRNA impairs the migration capacity of fibroblasts. These results demonstrate the importance of MuRF1 and MuRF2 during myogenic differentiation of skeletal muscle and an important role at intracellular coordination of stress fiber formation of skeletal muscle fibroblasts.

No description available.

Background: Oxidative stress due to reactive oxygen species (ROS) production is a key factor in the development of heart failure (HF). This study investigated the thioredoxin (Trx) system, which plays a major role in antioxidant defense, in patients suffering from ischemic (ICM) or dilated (DCM) cardiomyopathy. Methods and results: Myocardial tissue from ICM (n = 13) and DCM (n = 13) patients, as well as septal tissue of patients with aortic stenosis but without diagnosed hypertrophic cardiomyopathy or subaortic stenosis (control; n = 12), was analyzed for Trx1, Trx-interacting protein (TXNIP) and E3 ligase ITCH (E3 ubiquitin-protein ligase Itchy homolog) expression. Trx-reductase 1 (TXNRD1) amount and activity, cytosolic cytochrome C content, and apoptosis markers were quantified by means of enzyme-linked immunosorbent assay and multiplexing. Compared with control samples, ITCH and Trx1 expression, TXNRD1 amount and activity were reduced and TXNIP expression was increased in ICM (ITCH: P = .013; Trx1: P = .028; TXNRD1 amount: P = .035; TXNRD1 activity: P = .005; TXNIP: P = .014) but not in DCM samples. A higher level of the downstream apoptosis marker caspase-9 (ICM: 582 ± 262 MFI [P = .995]; DCM: 1251 ± 548 MFI [P = .002], control: 561 ± 214 MFI) was detected in DCM tissue. A higher expression of Bcl-2 was found in DCM (P = .011). Conclusion: The Trx system was impaired in ICM but not in DCM. ITCH appeared to be responsible for the down-regulation of the Trx system. ROS-induced mitochondrial instability appeared to play a role in DCM.

The pathological changes of ubiquitination and deubiquitination following myocardial infarction (MI) and chronic heart failure (CHF) have been sparsely examined. We investigated the expression of muscle-specific E3 ubiquitin ligases and deubiquitinases in MI and CHF. Therefore, mice were assigned to coronary artery ligation for 3 days or 10 weeks as well as for sham operation (each n = 10). Expression of E3 ligases (MAFBX, MURF1, CHIP, ITCH, MDM2) and deubiquitinases (A20, CYLD, UCH-L1, USP14, USP19) was determined. After MI and in CHF, the mRNA expression of MURF1, CHIP and MDM2 (all p < 0.05) was decreased. Protein expression analyses revealed that ITCH expression decreased in CHF (p = 0.01), whereas MDM2 expression increased in MI (p = 0.02) and decreased in CHF (p = 0.02). Except for USP19 mRNA expression that decreased at 3 days and 10 weeks (both p < 0.01), the expression of other deubiquitinases remained unaffected after MI and CHF. The expression of myocardial E3 ligases is differentially regulated following MI, raising the question of whether an upstream regulation exists that is activated by MI for tissue protection or whether the downregulation of E3 ligases enables myocardial hypertrophy following MI.

Dilated (DCM) and ischemic cardiomyopathies (ICM) are associated with cardiac remodeling, where the ubiquitin–proteasome system (UPS) holds a central role. Little is known about the UPS and its alterations in patients suffering from DCM or ICM. The aim of this study is to characterize the UPS activity in human heart tissue from cardiomyopathy patients. Myocardial tissue from ICM (n = 23), DCM (n = 28), and control (n = 14) patients were used to quantify ubiquitinylated proteins, E3-ubiquitin-ligases muscle-atrophy-F-box (MAFbx)/atrogin-1, muscle-RING-finger-1 (MuRF1), and eukaryotic-translation-initiation-factor-4E (eIF4E), by Western blot. Furthermore, the proteasomal chymotrypsin-like and trypsin-like peptidase activities were determined fluorometrically. Enzyme activity of NAD(P)H oxidase was assessed as an index of reactive oxygen species production. The chymotrypsin- (p = 0.71) and caspase-like proteasomal activity (p = 0.93) was similar between the groups. Trypsin-like proteasomal activity was lower in ICM (0.78 ± 0.11 µU/mg) compared to DCM (1.06 ± 0.08 µU/mg) and control (1.00 ± 0.06 µU/mg; p = 0.06) samples. Decreased ubiquitin expression in both cardiomyopathy groups (ICM vs. control: p < 0.001; DCM vs. control: p < 0.001), as well as less ubiquitin-positive deposits in ICM-damaged tissue (ICM: 4.19% ± 0.60%, control: 6.28% ± 0.40%, p = 0.022), were detected. E3-ligase MuRF1 protein expression (p = 0.62), NADPH-oxidase activity (p = 0.63), and AIF-positive cells (p = 0.50). Statistical trends were detected for reduced MAFbx protein expression in the DCM-group (p = 0.07). Different levels of UPS components, E3 ligases, and UPS activation markers were observed in myocardial tissue from patients affected by DCM and ICM, suggesting differential involvement of the UPS in the underlying pathologies.

Die Herzinsuffizienz ist aufgrund ihrer weltweit ansteigenden Prävalenz und den damit einhergehenden beträchtlichen Kosten im stationären sowie ambulanten Sektor von großer Relevanz für die globalen Gesundheitssysteme. Trotz multipler Möglichkeiten der pharmakologischen und chirurgischen Therapie ist die Mortalität weiterhin hoch. Die Etablierung neuer medikamentöser Behandlungsansätze ist daher von enormer Bedeutung und bedarf der Erweiterung des Verständnisses der pathophysiologischen Grundlagen der Erkrankung. Kardiomyopathien zählen zu den häufigsten Ursachen der Herzinsuffizienz. Dysfunktionen des Ubiquitin-Proteasom-Systems (UPS) wurden bereits in der Progression der Herzinsuffizienz bei Kardiomyopathien diskutiert und setzten einen potentiellen Fokus auf die E3-Ligasen. Diese Hypothese aufgreifend hatte die vorliegende Arbeit das Ziel, erstmalig den kompletten Myostatin/AKT/forkhead box protein (FOXO)-Signalweg und dessen Auswirkungen auf die E3-Ligasen muscle atrophy F-box gene (MAFbx) und muscle ring-finger protein-1 (MuRF1) im fortgeschrittenen humanen Kardiomyopathie-Stadium zu charakterisieren und mögliche neue Ansatzpunkte für die pharmakologische Therapie verschiedener Formen der Kardiomyopathie zu ermitteln. Zu diesem Zweck wurden Myokardproben von 26 Patienten mit ischämischer Kardiomyopathie (ICM), 23 Patienten mit dilatativer Kardiomyopathie (DCM) und 17 Kontrollpatienten molekularbiologisch, proteinbiochemisch und immunhistochemisch analysiert, um Veränderungen der Komponenten der Myostatin/AKT/FOXO-Signalkaskade und der E3-Ligasen MAFbx und MuRF1 zu identifizieren. Aus diesen Untersuchungen resultierten umfangreiche Alterationen des Signalwegs vor allem in DCM-Patienten. In dieser Gruppe war die Gen- und Proteinexpression der E3-Ligase MAFbx und des Transkriptionsfaktors FOXO1 gegenüber der Kontrollgruppe verringert. Weiterhin zeigte sich eine Reduktion von AKT auf der Genexpressionsebene und von Myostatin auf der Proteinebene in der DCM-Gruppe. Die ICM-Patienten wiesen mit Reduktionen der Genexpression von AKT und MAFbx sowie einem verringerten Anteil MuRF1-positiver Zellen in den immunhistochemischen Analysen nur geringe Unterschiede gegenüber der Kontrollgruppe auf. Die limitierten Veränderungen des Myostatin/AKT/FOXO-Signalwegs und der E3-Ligasen MAFbx und MuRF1 in ICM-Patienten lassen auf eine eher begrenzte Relevanz der Signalkaskade in der Pathophysiologie dieser Erkrankung schließen. Im Kontrast dazu stehen die detektierten Alterationen der analysierten Zielmoleküle in der DCM-Gruppe. Diese Divergenzen zeigen Unterschiede in der Pathogenese von ICM und DCM auf der Ebene des UPS. Daher unterstützt diese Arbeit die Hypothese, dass eine Therapieoptimierung dieser beiden Kardiomyopathien durch pharmakologische Adressierung verschiedener molekularer Ansatzpunkte erreicht werden könnte. In dieser Arbeit konnte die simultane Reduktion von MAFbx und FOXO1 in DCM-Patienten gezeigt werden. Durch die Validierung dieser synergistischen Regulation könnte FOXO1 einen potentiellen Angriffspunkt neuer medikamentöser Therapien der DCM darstellen. Unklar bleibt, ob die beobachtete Reduktion von MAFbx Ausdruck eines kardialen Schutzmechanismus oder der Progression des pathologischen Remodelings ist. Daher müssen weiterführende Studien klären, ob die E3-Ligase MAFbx über die therapeutische Beeinflussung des Transkriptionsfaktors FOXO1 herauf- oder herabreguliert werden sollte. Die Ergebnisse der vorliegenden Arbeit geben zudem einen Hinweis darauf, dass die Regulation von FOXO1 und MAFbx in DCM-Patienten nicht allein von Myostatin und AKT abhängig ist. Die Betrachtung weiterer Einflussfaktoren von MAFbx und FOXO1 in humanem Herzmuskelgewebe könnte somit ebenfalls Gegenstand zukünftiger Forschungsvorhaben sein. / Disturbances in the ubiquitin proteasome system, and especially changes of the E3 ligases, are subjects of interest when searching for causes and therapies for cardiomyopathies. The aim of this study was to clarify whether the myostatin/AKT/forkhead box O (FOXO) pathway, which regulates the expression of the E3 ligases muscle atrophy F-box gene (MAFbx) and muscle ring-finger protein-1 (MuRF1), is changed in dilated cardiomyopathy of ischemic origin (IDCM) and dilated cardiomyopathy of non-ischemic origin (NIDCM). The mRNA and protein expression of myostatin, AKT, FOXO1, FOXO3, MAFbx and MuRF1 were quantified by real-time polymerase chain reaction and ELISA, respectively, in myocardial tissue from 26 IDCM and 23 NIDCM patients. Septal tissue from 17 patients undergoing Morrow resection served as a control. MAFbx and FOXO1 mRNA and protein expression (all p < 0.05), AKT mRNA (p < 0.01) and myostatin protein expression (p = 0.02) were decreased in NIDCM patients compared to the control group. Apart from decreases of AKT and MAFbx mRNA expression (both p < 0.01), no significant differences were detected in IDCM patients compared to the control group. Our results demonstrate that the myostatin/AKT/FOXO pathway is altered in NIDCM but not in IDCM patients. FOXO1 seems to be an important drug target for regulating the expression of MAFbx in NIDCM patients.

[ES] El crecimiento de las plantas se ve afectado por el estrés abiótico, sequía, salinidad o altas temperaturas. La transducción de señales de estrés abiótico es fundamental para generar una respuesta fisiológica adecuada, que implica la participación de diferentes hormonas vegetales, siendo el ácido abscísico (ABA) el regulador hormonal crítico en la regulación de la respuesta de la planta a situaciones de estrés por déficit hídrico. La vía de señalización de ABA y los componentes principales están bien caracterizados molecular y bioquímicamente. Los receptores de ABA "Pyrabactin Resistance 1"(PYR)/"PYR1-LIKE" (PYL)/ "Regulatory Component of ABA Receptor" (RCAR) juegan un papel importante en la regulación cuantitativa de la señalización ABA tanto en semillas como en tejidos vegetativos. Aunque la función bioquímica de los receptores PYR/PYL/RCARs de ABA, está bien caracterizada, se conoce poco sobre otros aspectos con relevancia biológica, como sus modificaciones postraduccionales o la regulación de su vida media. Uno de los avances recientes en este campo ha sido el descubrimiento de una nueva familia de E3 ligasas llamadas RSL1/RFAs ("RING-finger-ABA-related") que consta de al menos 10 miembros, reguladores clave de la estabilidad de los receptores PYR/PYL/RCAR de ABA en tejidos de raíces y hojas, regulando su degradación en diferentes ubicaciones celulares. Un estudio detallado de esta familia génica reveló que RSL1/RFA se caracterizan estructuralmente por la presencia de tres dominios RING putativos en tándem, denominados "RING1-IN BETWEEN RING-RING2" (RBR), y en consecuencia pertenecen a la familia de E3 ligasas de tipo RBR. Cinco miembros de la familia RSL1/RFA, RSL1 y RFA6-RFA9, contienen un dominio TM en el extremo C-terminal, lo que sugiere que RFA6-RFA9 también se localizan en la membrana plasmática. Sin embargo, otros miembros de las E3 ligasas como RFA1-RFA5 carecen del dominio TM C-terminal y su caracterización funcional, así como su ubicación celular, aún no se conocen. Nosotros mostramos que la E3 ligasa RFA1 se localiza en núcleo y citosol, mientras que RFA4 muestra una localización específica en el núcleo promoviendo la degradación nuclear de los receptores ABA. Por lo tanto, los miembros de la familia RSL1/RFA interactúan con los receptores ABA en la membrana plasmática, el citosol y el núcleo, dirigiéndolos a su degradación a través de la vía endosomal/vacuolar (en el caso de RSL1) o el proteosoma 26S (para RFA1 y RFA4). Proporcionamos información sobre la función fisiológica de estas E3 ligasas de tipo RBR. Realizando tanto mutagénesis como ensayos bioquímicos para identificar la cisteína 361 (Cys361) en RFA4 como la Cys del sitio activo, que es una característica distintiva de las E3 ligasas de tipo RBR. Demostramos mediante análisis de inmunotransferencia del mutante con pérdida de función de rfa1rfa4 que los niveles endógenos de los receptores de ABA PYR1 y PYL4 aumentan en comparación con las plantas de tipo silvestre. Hemos identificado una enzima E2, "Ubiquitin Conjugating Enzyme 26" (UBC26), como la enzima nuclear canónica E2 que interactúa con la E3 ligasa RFA4 y forma complejos UBC26-RFA4-Receptor, formando agregados nucleares. Generamos alelos ubc26 con pérdida de función que mostraban una mayor sensibilidad a ABA y acumulación de receptores ABA en comparación con el tipo silvestre. En definitiva, hemos revelado un sofisticado sistema de ubiquitinación de receptores ABA en diferentes ubicaciones subcelulares llevado a cabo a través de la familia de E3 ligasas RSL1/RFA de tipo RBR. Por otro lado, hemos iniciado pruebas bioquímicas para identificar la S-acilación en el dominio TM de RSL1. Generando RSL1C334S, RSL1 C5S y RSL1C6S mediante mutagénesis y RSL1ΔTM que presenta una delección del dominio TM. Los estudios iniciales han demostrado que los residuos de Cys cercanos al dominio TM están S-acilados. Finalmente, generamos nu / [CA] El creixement de les plantes es pot veure afectat per l'estrès abiòtic, sequera, salinitat o altes temperatures. La transducció de senyals d'estrès abiòtic és fonamental per a generar una resposta fisiològica adequada, que implica la participació de diferents hormones vegetals, sent l'àcid abscísic (ABA) el regulador hormonal crític en la regulació de la resposta de la planta a situacions d'estrès per dèficit hídric. La ruta de senyalització d'ABA i els components principals de la ruta estan ben caracteritzats molecularment i bioquímica. Els receptors "Pyrabactin Resistance 1"(PYR)/"PYR1-LIKE"(PYL)/"Regulatory Component of ABA Receptor" (RCAR) exerceixen un paper important en la regulació quantitativa en resposta a l'estrès tant en llavors com en planta. Encara que la funció bioquímica dels receptors PYR/PYL/RCARs d'ABA, està ben caracteritzada en els últims anys, es coneix poc sobre altres aspectes amb rellevància biològica, com les seues modificacions postraduccionals o la regulació de la seua vida mitjana. Un dels avanços recents en aquest camp ha sigut el descobriment d'una nova família d'E3 ligases anomenades RSL1/RFAs ("RING-finger-ABA-related") que consta d'almenys 10 membres, que són reguladors clau de l'estabilitat dels receptors PYR/PYL/RCAR d'ABA en teixits d'arrels i fulles, regulant la seua degradació en diferents ubicacions cel·lulars. Un estudi més detallat d'aquesta família gènica va revelar que RSL1/RFAs es caracteritzen estructuralment per la presència de tres dominis RING putatius en tàndem, denominats "RING1-IN BETWEEN RING-RING2" (RBR), i en conseqüència pertanyen a la família d'E3 ligases de tipus RBR. Cinc membres de la família RSL1/RFA, RSL1 i RFA6-RFA9, contenen un domini TM en l'extrem C-terminal, la qual cosa suggereix que RFA6-RFA9 també es localitzen en la membrana plasmàtica. No obstant això, altres membres d'aquesta família d'E3 ligases com RFA1-RFA5 manquen del domini TM C-terminal i la seua caracterització funcional, així com la seua ubicació cel·lular, encara no ha sigut investigada. Vam mostrar que l'E3 ligasa RFA1 es localitza tant en el nucli com en el citosol, mentre que RFA4 mostra una localització específica en el nucli promovent la degradació nuclear dels receptors ABA. Per tant, els membres de la família RSL1/RFA interactuen amb els receptors ABA en la membrana plasmàtica, el citosol i el nucli, dirigint-los a la seua degradació a través de la vía endosomal/vacuolar (en el cas de RSL1) o el proteosoma 26S (per a RFA1 i RFA4). Proporcionem informació sobre la funció fisiològica d'aquestes E3 ligases de tipus RBR. Realitzant tant mutagènesis com a assajos bioquímics per a identificar la cisteïna 361 (Cys361) en RFA4 com la Cys del lloc actiu, que és una característica distintiva de les E3 ligases de tipus RBR. Hem demostrat mitjançant una anàlisi d'immuno-transferència del mutant amb pèrdua de funció de rfa1rfa4 que els nivells endògens dels receptors d'ABA PYR1 i PYL4 augmenten en comparació amb les plantes de tipus silvestre. D'altra banda, hem identificat un enzim E2, "Ubiquitin Conjugating Enzyme 26" (UBC26), com l'enzim nuclear canònic E2 que interactua amb l'E3 ligasa RFA4 i forma complexos UBC26-RFA4-Receptor, formant agregats nuclears. També generem al·lels ubc26 amb pèrdua de funció que mostraven una major sensibilitat a ABA i acumulació de receptors ABA en comparació amb el tipus silvestre. En definitiva, hem revelat un sofisticat sistema d'ubiquitinació de receptors ABA en diferents ubicacions subcel·lulars dut a terme a través de la família d'E3 ligases RSL1/RFA de tipus RBR. Hem iniciat proves bioquímiques per a identificar la S-acilació en el domini TM de RSL1. Hem generat RSL1C334S, RSL1 C5S i RSL1C6S mitjançant mutagènesis, així com RSL1ΔTM que presenta una delecció del domini TM. Els estudis inicials han demostrat que els residus de Cys pròxims al domini TM estan S-acilados. Final / [EN] Plant growth is affected by abiotic stress, drought, salinity or high temperature. Signal transduction of abiotic stress is crucial to generate an appropriated physiological response, which involves the participation of different plant hormones, being abscisic acid (ABA) the critical hormonal regulator in regulating the plant's response to situations of stress due to water deficit. The ABA signaling pathway and the major components of the pathway are well characterized molecularly and biochemically. Pyrabactin Resistance 1 (PYR)/PYR1-LIKE (PYL)/Regulatory Component of ABA Receptor (RCAR) ABA receptors play an important role in quantitative regulation of ABA signaling both in seeds and vegetative tissues. Although the biochemical function of the PYR/PYL/RCAR ABA receptors has been well established in recent years, little is known about other aspects with biological relevance, such as their post-translational modifications or the regulation of their half-life. One of the recent advances in this field has been the discovery of a new family of E3 ligases called RSL1/RFAs (RING-finger-ABA-related) that consists of at least 10 members, which are key regulators of the stability of PYR/PYL/RCARs in root and leaf tissues, and regulate the degradation of ABA receptors at different cellular locations. Further inspection of the gene family revealed that RSL1/RFAs are structurally characterized by the presence of three putative RING domains in tandem, named as RING1-IN BETWEEN RING (IBR)-RING2, and accordingly they belong to the RBR-type E3 ligase family. Five members of the RSL1/RFA family, that is, RSL1 and RFA6-RFA9, contain a TM domain at the C-terminal end of the proteins, which suggests that RFA6-RFA9 are also localized in plasma membrane. However, other members of this family of E3 ligases such as RFA1-RFA5 lack the C-terminal TM domain and their functional characterization, as well as their cellular location, has not been investigated yet. In this study we show that the E3 ligase RFA1 is localized both in the nucleus and in the cytosol, while RFA4 shows a specific localization in the nucleus promoting the nuclear degradation of ABA receptors. Therefore, we members of the RSL1/RFA family interact with ABA receptors at the plasma membrane, cytosol and nucleus, targeting them for degradation via the endosomal/vacuolar pathway (in the case of RSL1) or the 26S- proteasome (for RFA1 and RFA4). We provide information on the physiological function of these RBR-type E3 ligases, which are hardly explored in plants. Additionally, we performed mutagenesis and biochemical assays to identify Cys361 in RFA4 as the active site cysteine, which is a distinctive feature of RBR-type E3 ligases. We have shown by immunoblot analysis of the rfa1rfa4 loss-of-function mutant that endogenous levels of ABA receptors PYR1 and PYL4 are increased compared to wild-type plants. On the other hand, we have identified an E2 enzyme, Ubiquitin Conjugating Enzyme 26 (UBC26), as the canonical nuclear enzyme E2 that interacts with the E3 ligase RFA4 and forms UBC26-RFA4-Receptor complexes, forming nuclear aggregates. We also generated loss-of function ubc26 alleles that exhibited higher sensitivity to ABA and accumulation of ABA receptors compared to wild type. We have revealed a sophisticated ubiquitination system of ABA receptors in different subcellular locations carried out through the RBR-type RSL1/RFA family of E3 ligases. We have proceeded with the biochemical and genetic study of the different members of the family. We have started biochemical tests to identify the S-acylation in the TM domain of RSL1. To this end, we have generated RSL1C334S, RSL1 C5S and RSL1C6S by mutagenesis as well as RSL1ΔTM, a deletion of the TM domain. Initial studies have shown that Cys residues close to the TM domain are S-acylated. Finally, we have also generated new combined mutants: rsl1rfa1, rsl1rfa5, rfa1rfa5 and rsl1rfa1rfa5. / Fernández López, MA. (2021). Regulación de la señalización del ABA mediante mecanismos que controlan vida media y actividad de los receptores PYR/PYL [Tesis doctoral]. Universitat Politècnica de València. https://doi.org/10.4995/Thesis/10251/172364